Explore /
Poster
/ The phase II study of efficacy and safety of oxaliplatin with doxorubicin in recurrent ovarian cancer (OC).

The phase II study of efficacy and safety of oxaliplatin with doxorubicin in recurrent ovarian cancer (OC).

Authors

I. Pokataev

N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia

I. Pokataev , G. M. Manikhas , V. Borisov , M. Stenina , A. Tjulandina , S. Tjulandin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Citation

J Clin Oncol 29: 2011 (suppl; abstr 5087)

Abstract #

5087

Poster Bd #

20C

Abstract Disclosures

Similar Posters

Poster

2020 ASCO Virtual Scientific Program

A Big Ten Cancer Research Consortium phase II trial of pembrolizumab with carboplatin and paclitaxel for advanced or recurrent endometrial cancer.

A Big Ten Cancer Research Consortium phase II trial of pembrolizumab with carboplatin and paclitaxel for advanced or recurrent endometrial cancer.

First Author: Mario Javier Pineda

Poster

2022 ASCO Annual Meeting

Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with platinum) followed by camrelizumab combined with apatinib in the first-line treatment of advanced small cell lung cancer: A phase II study.

Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with platinum) followed by camrelizumab combined with apatinib in the first-line treatment of advanced small cell lung cancer: A phase II study.

First Author: Jun Ni

Poster

2020 ASCO Virtual Scientific Program

The safety and efficacy of weekly paclitaxel and cisplatin chemotherapy for patients with ovarian cancer who developed carboplatin hypersensitivity reaction in previous chemotherapy.

The safety and efficacy of weekly paclitaxel and cisplatin chemotherapy for patients with ovarian cancer who developed carboplatin hypersensitivity reaction in previous chemotherapy.

First Author: Kyoko Nishikimi

Poster

2017 ASCO Annual Meeting

Panitumumab in platinum-sensitive epithelial ovarian cancer patients with KRAS wild-type: The PROVE-study, a phase II randomized multicenter study of the North-Eastern German Society of Gynaecologic Oncology<em></em>.

Panitumumab in platinum-sensitive epithelial ovarian cancer patients with KRAS wild-type: The PROVE-study, a phase II randomized multicenter study of the North-Eastern German Society of Gynaecologic Oncology.

First Author: Radoslav Chekerov